TrialPediatric blood & cancer2015

Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2.

Elizabeth A Raetz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.